Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jul;78(1):78-83.
doi: 10.1111/bcp.12295.

Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia

Simone M C Spoorenberg  1 , Vera H M Deneer, Jan C Grutters, Astrid E Pulles, G P Paul Voorn, Ger T Rijkers, Willem Jan W Bos, Ewoudt M W van de Garde
Affiliations
Randomized Controlled Trial

Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia

Simone M C Spoorenberg et al. Br J Clin Pharmacol. 2014 Jul.

Abstract

Aim: The use of corticosteroids as adjunctive therapy might be effective in patients with community-acquired pneumonia (CAP). Oral administration of dexamethasone is a practical and safer alternative to the intravenous route. Since patients hospitalized with pneumonia might have delayed gastric emptying, this study explored systemic exposure in terms of area under the concentration-time curve (AUC) of oral dexamethasone in patients hospitalized with CAP.

Methods: In this randomized, open label study, 30 patients admitted with CAP were randomized to receive either 4 mg intravenous or 6 mg oral dexamethasone for 4 consecutive days. Serial blood samples were obtained before and after drug administration.

Results: Median AUC to infinity was 626 μg l(-1) h (IQR 401-1161) for the intravenous group and 774 μg l(-1) h (IQR 618-1146) for the oral group. The AUC ratio of 6 mg oral and 4 mg intravenous dexamethasone was 1.22 (95% confidence interval (CI) 0.81, 1.82), which represents a bioavailability of 81% (95% CI 54, 121) after correction for differences in dexamethasone dose.

Conclusions: Bioavailability of oral dexamethasone in patients hospitalized with pneumonia is sufficient. This makes oral dexamethasone an appropriate alternative for intravenous administration in these patients.

Keywords: CAP; bioavailability; community-acquired pneumonia; dexamethasone; intravenous; oral.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Median dexamethasone concentrations at each time point in μg l−1 with interquartile range. (formula image) Oral, (formula image) intravenous, (formula image) extrapolated intravenous maximum, (…) detection limit
See this image and copyright information in PMC

References

    1. Nugent CA, Nichols T, Tyler FH. Diagnosis of Cushing's syndrome; sngle dose dexamethasone suppression test. Arch Intern Med. 1965;116:172–176. - PubMed
    1. Galicich JH, French LA, Melby JC. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. J Lancet. 1961;81:46–53. - PubMed
    1. McIntyre PB, Berkey CS, King SM, Schaad UB, Kilpi T, Kanra GY, Perez CM. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA. 1997;278:925–931. - PubMed
    1. Fernandez-Serrano S, Dorca J, Garcia-Vidal C, Fernandez-Sabe N, Carratala J, Fernandez-Aguera A, Corominas M, Padrones S, Gudiol F, Manresa F. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care. 2011;15:R96. - PMC - PubMed
    1. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171:242–248. - PubMed

Publication types